- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Medicenna Therapeutics Corp: Medicenna to present MDNA11 update at AACR | 1 | Stockwatch | ||
| Mi | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 25.02. | Medicenna Therapeutics Corp: Medicenna talks MDNA11 Ability-1 study data | 1 | Stockwatch | ||
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.02. | Medicenna Therapeutics Corp.: Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones | 109 | GlobeNewswire (Europe) | - Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck's (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1... ► Artikel lesen | |
| 05.02. | Stocks in Play: Medicenna Therapeutics Corp | - | Baystreet.ca | ||
| 10.01. | Insider Buying: Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer Buys 20,000 Shares of Stock | 2 | MarketBeat | ||
| 13.12.24 | Medicenna Therapeutics Corp.: Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS) | 1 | GlobeNewswire (USA) | ||
| 05.12.24 | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 05.12.24 | Medicenna Therapeutics Corp.: Medicenna Provides Clinical Update and Announces First Complete Response in MDNA11 in Combination with KEYTRUDA (pembrolizumab) Dose Escalation Arm of the ABILITY-1 Study | 123 | GlobeNewswire (Europe) | 70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck's (known as MSD outside of the US and Canada)... ► Artikel lesen | |
| 27.11.24 | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 27.11.24 | Medicenna to present updated ABILITY-1 study data | - | Investing.com | ||
| 25.11.24 | Medicenna Therapeutics Corp.: Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) | 1 | GlobeNewswire (USA) | ||
| 15.11.24 | Medicenna Therapeutics GAAP EPS of -C$0.05 | 2 | Seeking Alpha | ||
| 15.11.24 | Medicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update | 154 | GlobeNewswire (Europe) | MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression... ► Artikel lesen | |
| 13.11.24 | Medicenna Therapeutics Corp.: Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS) | 3 | GlobeNewswire (USA) | ||
| 11.11.24 | Medicenna Therapeutics Corp: Medicenna talks MDNA11 Ability-1 study results | 2 | Stockwatch | ||
| 11.11.24 | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 11.11.24 | Medicenna Therapeutics Corp.: Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA (pembrolizumab) at the ... | 129 | GlobeNewswire (Europe) | Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression with... ► Artikel lesen | |
| 08.11.24 | Medicenna Therapeutics Corp.: Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | 176 | GlobeNewswire (Europe) | MDNA113 is a novel IL-13Ra2 tumor-targeted and "masked" BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor microenvironment... ► Artikel lesen | |
| 15.10.24 | OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX | 121 | GlobeNewswire (Europe) | NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna Therapeutics... ► Artikel lesen |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,135 | +1,25 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
| TEMPUS AI | 46,860 | -2,86 % | Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? | ||
| BIOAFFINITY TECHNOLOGIES | 1,120 | +307,27 % | RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 13,870 | -12,82 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 6,125 | +1,07 % | Evotec-Aktie: Crash auf 4 Euro voraus? Behält die Deutsche Bank Recht mit Ihrem Kursziel? | © Foto: Symbolbild von pina messina auf UnsplashKooperationen mit Pharma-Giganten, Hightech-Forschung und trotzdem bewegt sich die Evotec-Aktie nicht richtig nach oben. Die Deutsche Bank warnte vor... ► Artikel lesen | |
| BIONTECH | 84,90 | +2,97 % | EQS-News: CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE
27.03.2025... ► Artikel lesen | |
| BEAM THERAPEUTICS | 17,720 | -9,34 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| BB BIOTECH | 31,900 | +0,31 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,100 | -3,50 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
| SPRINGWORKS THERAPEUTICS | 41,990 | -4,89 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| IMMUNOVANT | 15,315 | -10,33 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
| NUVALENT | 69,25 | -2,30 % | Nuvalent-Entwicklungschefin verkauft Aktien im Wert von 292.468 US-Dollar | ||
| SUMMIT THERAPEUTICS | 18,870 | -2,20 % | Cantor Fitzgerald maintains Overweight on Summit Therapeutics shares | ||
| KYMERA THERAPEUTICS | 25,370 | -7,38 % | Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.2% - Should You Sell? | ||
| ARCELLX | 60,58 | -7,71 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen |
Das Unternehmen MEDICENNA THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.
